Company Overview

PureTech Health plc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for major diseases with significant unmet medical need. The company operates at the intersection of biotechnology, pharmaceutical research, and therapeutic platform development, with a strategic emphasis on neuroscience, immunology, inflammation, and gastrointestinal (GI) diseases. Its business model combines internal drug development with the creation and support of founded entities that advance distinct therapeutic programs.

PureTech’s primary value drivers are its proprietary therapeutic candidates, most notably deupirfenidone (formerly LYT-100) for idiopathic pulmonary fibrosis and related indications, as well as its ownership stakes in founded companies such as Karuna Therapeutics, Gelesis, and Vor Bio. The company differentiates itself through its “brain-gut-immune” axis approach, leveraging systems biology and platform science to generate novel drug candidates. Founded in 2015, PureTech evolved from a venture creation and incubation model into a more focused operating biopharmaceutical company while retaining significant equity interests in select subsidiaries and associates.

Business Operations

PureTech’s operations are organized around two core activities: internal drug development and strategic ownership in founded entities. Internally, the company advances wholly owned clinical and preclinical programs, generating value through clinical milestones, intellectual property development, and potential commercialization or partnering. Revenue generation historically has been limited and episodic, primarily derived from milestone payments, royalties, and equity monetization rather than product sales.

The company maintains domestic operations in the United Kingdom and United States, with research, clinical development, and corporate functions split across these regions. PureTech controls proprietary platforms related to drug formulation, immune modulation, and systems pharmacology. Its business structure includes majority and minority stakes in subsidiaries and associates such as PureTech LYT, Inc., Karuna Therapeutics, Gelesis, and Vor Bio, with varying degrees of operational involvement depending on ownership and governance rights.

Strategic Position & Investments

PureTech’s strategic direction centers on advancing late-stage clinical assets while selectively realizing value from its portfolio through partnerships, spin-outs, or equity sales. A key strategic milestone was the monetization of its stake in Karuna Therapeutics, which significantly influenced capital allocation and balance sheet strength. The company continues to prioritize capital efficiency, focusing investment on programs with clear clinical differentiation and regulatory pathways.

The company remains active in emerging therapeutic areas, including neuropsychiatric disorders, immune-mediated diseases, and metabolic health. Investments are guided by translational science and platform reuse, enabling multiple indications to be pursued from shared technological foundations. While PureTech does not routinely engage in large-scale acquisitions, it selectively invests in or incubates new entities aligned with its core scientific strategy.

Geographic Footprint

PureTech Health plc is headquartered in London, United Kingdom, with a substantial operational presence in Boston, Massachusetts, United States, a major global biotechnology hub. These two regions serve as the company’s primary centers for executive leadership, research collaboration, and clinical development oversight.

Beyond its core locations, PureTech’s influence extends internationally through global clinical trials, collaborations with academic institutions, and investments in companies operating across North America and Europe. While the company does not maintain extensive physical infrastructure outside these regions, its portfolio companies and clinical programs provide indirect exposure to multiple international markets.

Leadership & Governance

PureTech was founded by Daphne Zohar, who has played a central role in shaping the company’s venture creation model and long-term scientific vision. The leadership team emphasizes disciplined capital deployment, translational science, and long-duration value creation rather than short-term revenue generation. Governance is structured to balance operating company priorities with oversight of strategic equity holdings.

Key executives include:

• Daphne Zohar – Founder and Chief Executive Officer
• Yamini Edwards – Chief Operating Officer
• Russell Cox – Chief Financial Officer
• Joanna Horobin – Chief Medical Officer
• Peter Svennilson – Managing Partner and Board Member

The leadership team collectively brings experience across drug development, finance, clinical medicine, and biotechnology company building, reinforcing PureTech’s hybrid operating and investment-focused strategy.